Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
egaptivon pegol
- Development stage
- Phase 2
- Lead developer
- Baxter
- Modality
- RNA Aptamers → RNA Therapeutics → Nucleic Acid Therapeutics, DNA Aptamers → DNA Therapeutics → Nucleic Acid Therapeutics, Recombinant Proteins and Enzymes
- Administration
- Intravenous
01
Overview
Egaptivon pegol is a PEGylated DNA aptamer that acts as an antagonist of the A1 domain of von Willebrand factor (vWF), thereby inhibiting its interaction with the platelet glycoprotein Ib (GPIb) receptor. This mechanism blocks vWF-mediated platelet adhesion, activation, and aggregation under high shear conditions, such as those found in coronary arterial stenosis and plaque rupture. Egaptivon pegol was developed for antithrombotic therapy and investigated primarily for thrombotic thrombocytopenic purpura (TTP) and acute coronary syndromes. It is a second-generation aptamer with enhanced properties due to PEGylation[1][2][7].
- Other names
- egaptivon pegol sodium
02
Targets
BB-031 (Von Willebrand factor)
Beyond the preview
Go deeper on egaptivon pegol.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on egaptivon pegol.